Immatics to Sell 12.5 Million Shares in $125 Million Underwritten Offering

Immatics, a clinical-stage biopharmaceutical company, has agreed to sell 12.5 million ordinary shares at $10 per share, raising $125 million in gross proceeds. The offering is expected to close on December 8, 2025, subject to customary conditions, and will be managed by Jefferies, Leerink Partners, and Cantor. The proceeds will be used for general corporate purposes.